BeiGene Ltd. announced that the commercial-stage biopharmaceutical company’s investigational BTK inhibitor zanubrutinib was granted Fast Track designation by the U.S. FDA for the treatment of patients with Waldenström macroglobulinemia.
Company Also Bolsters Board of Directors and Scientific Advisory Board with Outstanding Leaders BOSTON–(BUSINESS WIRE)–SQZ Biotech (SQZ) announced today a partnership with Roche to develop a cell therapy platform that […]
